Nutriband Inc.
NASDAQ:NTRBBiotechnology
+$0.85 today
- Market cap
- $58.59M
- Beta
- 1.97
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.66
Volume 0.03M
Average 0.01M
NTRB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Nutriband Inc.NASDAQ: NTRB
Net Income · Q1 FY2026 · quarter ended Apr 2026
Net income declines year over year
Q1 FY2026 net income of $1.24M (cash outflow) fell 10.6% year over year, ahead of the -19.0% change in trailing-twelve-month net income. Sequentially, it rose 28.3% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.
Context
- Net income amounted to 404.1% of revenue in FY2025, down 85.8 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of $18.28M (+322.1%) for the fiscal year ending Jan 2027, a step up from the -21.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- -$1.24M+28.3% QoQ
- Last fiscal yearJan 2026
- -$8.23M-21.5% YoY
- LTMApr 2026
- -$8.08M-19.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.6% | +100.0% | +110.6 pp |
| 1 year | -21.5% | +322.1% | +343.6 pp |
| 3-year CAGR | +22.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (8.23M) USD
- Year-over-year change
- +21.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-31 | (8.23M) | +21.5% |
| FY2024 | 2025-01-31 | (10.48M) | -91.1% |
| FY2023 | 2024-01-31 | (5.49M) | -22.3% |
| FY2022 | 2023-01-31 | (4.48M) | +27.4% |
| FY2021 | 2022-01-31 | (6.18M) | — |
Net Income vs competitors
How NTRB compares with its peers on the latest reported figures
- NTRB's LTM Apr 2026 net income of $8.08M is the smallest of the 9 companies compared; the peer median is $49.52M.
- Its year-over-year change of -19.0% is the 7th highest of 8, against a peer median of -5.5%.
- Net income amounts to 448.4% of revenue for NTRB, versus a peer median of 1360.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.31M | -5.5% | +25.1% | 1360.6% | |
| LTM Mar 2026 | $108.83M | -7.2% | +18.7% | — | |
| LTM Mar 2026 | $102.15M | +215.2% | -46.4% | 154.4% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M | -7.7% | +35.7% | — |
| LTM Mar 2026 | $58.88M | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $40.16M | +1.9% | +11.4% | — | |
| LTM Jun 2024 | $31.85M | — | -39.6% | 3904.3% | |
| LTM Mar 2026 | $21.24M | +1.5% | +4.7% | — | |
| LTM Apr 2026 | $8.08M | -19.0% | +22.4% | 448.4% | |
| Peer median (excluding NTRB) | $49.52M | -5.5% | +8.0% | 1360.6% | |
Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jan 2022 | FY2022 Jan 2023 | FY2023 Jan 2024 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Net Income | (6.18M) | (4.48M) | (5.49M) | (10.48M) | (8.23M) |
| Depreciation & Amortization | 318.26K | 368.96K | 287.72K | 285.05K | 193.8K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 897.83K | 732.13K | 742.7K | 1.54M | 104.4K |
| Change in Working Capital | (541.38K) | (219.32K) | 223.22K | 34.09K | 126.81K |
| Accounts Receivables | 42.97K | (41.67K) | (153.97K) | 74.8K | (44.56K) |
| Inventory | (78.8K) | (97.69K) | 60.73K | (43.44K) | 94.05K |
| Accounts Payables | (145.26K) | (104.86K) | 198.89K | 23.61K | 120.94K |
| Other Working Capital | (360.29K) | 24.9K | 117.57K | (20.89K) | (43.63K) |
| Other Non-Cash Items | 2.23M | 614.51K | 704.17K | 3.99M | 2.67M |
| Operating Cash Flow | (2.81M) | (2.99M) | (3.53M) | (4.63M) | (5.13M) |
| Capital Expenditures | (81.6K) | (79.3K) | (51.76K) | (92.04K) | (5.32K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (81.6K) | (79.3K) | 0 | 0 | 0 |
| Investing Cash Flow | (81.6K) | (79.3K) | (51.76K) | (92.04K) | (5.32K) |
| Debt Repayment | (1.63M) | (17.8K) | 2.09M | 8.69M | (21.62K) |
| Common Stock Issued | 6.42M | 0 | 2.61M | 8.41M | 5.42M |
| Common Stock Repurchased | (104.47K) | (119.01K) | 0 | (149K) | 0 |
| Dividends Paid | (196.59K) | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.14M | 296.88K | 0 | 69 | 0 |
| Financing Cash Flow | 7.63M | 160.07K | 2.09M | 8.54M | 5.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 4.74M | (2.91M) | (1.49M) | 3.82M | 263.14K |
| Free Cash Flow | (2.89M) | (3.07M) | (3.58M) | (4.72M) | (5.13M) |
Nutriband Inc.
NASDAQ:NTRB
Intrinsic Alpha fair value
Locked
Current Price
$4.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.